The global Circulating Tumor Cell Market size is expected to reach around USD 23.9 billion by 2027 at a CAGR of 13.2% over the forecast period, according to a new report by Grand View Research, Inc. The growth in cancer-related spending for the introduction of companion diagnostics and targeted therapies has driven the circulating tumor cell (CTC) market over the past years. Research organizations are engaged in endeavors aimed at developing circulating tumor cells based tests to improve cancer diagnosis in terms of efficiency and speed.
Furthermore, the growing demand for minimally invasive
diagnostic procedures is anticipated to propel investments by key stakeholders
in this area. Circulating tumor cell based liquid biopsy tests lead to limited
trauma and enable rapid recovery owing to their non-invasive nature. Moreover,
it enables minimal invasive screening of tumors before opting for complex
surgical procedures, such as radiotherapy, chemotherapy, and surgical removal
of tumors, thus positively impacting the adoption.
The limited applicability of these cells in rare
cancers has hampered the revenue growth up to a certain extent. For instance,
there is a negligible evidence for the characterization of circulating tumor
cells for sarcoma. Conversely, several methods are being investigated for
isolation of these cells, such as methods based on epithelial antigen-targeted
antibodies, which are anticipated to help overcome these challenges in the
coming years.
Request a sample copy or view summary of this report@
https://www.grandviewresearch.com/industry-analysis/circulating-tumor-cells-market
Further key findings from the
report suggest:
- CTC
detection and enrichment methods accounted for the largest revenue share
owing to the presence of wide availability of products for CTC enrichment
and isolation
- Moreover,
high penetration in terms of usage of products offered under this segment
has driven the segment share
- Growing
application of nanomaterials in cancer management is anticipated to drive
revenue for direct detection methods in the coming years
- Devices
and systems dominated the revenue share in 2019 over its counterpart
segments including kits and reagents and blood collection tubes
- Presence
of high-throughput automated systems coupled with the availability of a
substantial number of systems to carry out detection of tumor cells has
contributed to large revenue share
- CTC
analysis has major applications in research settings, including
investigational research, drug developments, and biomarker studies. This
has resulted in a segment’s large revenue share
- Currently,
whole blood specimens are the key source of CTCs, thus accounting for the
largest share in 2019
- Low
use of bone marrow-derived cells in clinical settings has contributed to a
smaller revenue share of this segment
- Other
sources include CSF, spinal fluids, urine, and pleural effusion
- Easy
availability of biological specimens, such as urine, is likely to
accelerate adoption under this segment
- The
CTC market is fragmented in nature with the presence of well-established
players, along with medium to small-sized players
- Some
players operating in the space are QIAGEN; Greiner Bio One International
GmbH; Menarini Silicon Biosystems; Sysmex Corporation; Bio-Techne
Corporation; and Biocept, Inc.
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment